CervoMed reports early biomarker data from nfvPPA drug trial
Tweet Send to a Friend
CervoMed Inc. (NASDAQ: CRVO) announced initial 12-week biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




